Cardiology

BRAF+

Questions discussed in this category

Would you discontinue dabrafenib/trametinib in a patient with BRAF mutant metastatic lung cancer if you see mild cardiomyopathy which could be related to the drugs?

Patient does not want chemo but is tolerating these well otherwise.

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2014-11-13

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

Lancet Oncol., 2017 Sep 11

Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

Related Topics in Cardiology